Moleculin Announces New Independent Study Expands Potential Use of Its Pancreatic Drug Candidate WP1122 Nov 8, 2018
Moleculin Announces New Data Discovery Confirming Significant Increase in Potential to Starve Cancerous Tumors Oct 10, 2018
Moleculin’s Brain Cancer Drug Candidate Begins Patient Dosing at Clinical Trial Being Conducted at MD Anderson Sep 13, 2018
Moleculin Biotech, Inc. Reports Financial Results for the Second Quarter Ended June 30, 2018 Aug 13, 2018
Moleculin Expects to Meet FDA IND Filing Requirements for its Pancreatic Cancer Drug Candidate with Development Work in Australia Jul 18, 2018
Moleculin Expands Operations to Australia; Taps R&D Incentive Program Capped at $20,000,000 AUD Turnover Jul 11, 2018
